BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Information Letter on flupirtine: recall and revocation of marketing authorisation

Active substance: flupirtine

Following the European benefit-risk assessment, marketing authorisations of medicinal products containing the active substance flupirtine are revoked on an EU-wide level due to the risk of liver damage.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 36KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK